**A Systematic Review of Smoking Cessation Interventions for Adults in Substance Abuse Treatment or Recovery**

**Thurgood SLa, McNeill Ab, Clark-Carter Dc, Brose LSd**

a ***Corresponding Author:*** *Sarah L Thurgood MSc****,*** *Centre for Health Psychology, Staffordshire University, Science Centre, Leek Road, Stoke-on-Trent, ST4 2DF, United Kingdom, Thurgood.sarah@gmail.com. +44(0)7852108260*

b *Professor Ann McNeill PhD, Addictions, UK Centre for Tobacco and Alcohol Studies (UKCTAS), Institute of Psychiatry, Kings College London, 4 Windsor Walk, Denmark Hill, London, SE5 8PB United Kingdom.* *ann.mcneill@kcl.ac.uk*

c *Professor David Clark-Carter PhD, Centre for Health Psychology, Staffordshire University, Science Centre, Leek Road, Stoke-on-Trent, ST4 2DF, United Kingdom* D.Clark-Carter@staffs.ac.uk

d *Dr Leonie Brose PhD, Addictions, UK Centre for Tobacco and Alcohol Studies (UKCTAS), Institute of Psychiatry, Kings College London, 4 Windsor Walk, Denmark Hill, London, SE5 8PB United Kingdom. leonie.brose@kcl.ac.uk*

**Running Head: Smoking cessation and substance abuse**

**Word Count: 4028, max for reviews 6000**

**A Systematic Review of Smoking Cessation Interventions for Adults in Substance Abuse Treatment or Recovery**

Introduction: The aim was to evaluate the effectiveness of smoking cessation interventions for patients with substance use disorders. The secondary aim was to evaluate impact on substance use treatment outcomes.

Methods: Randomised controlled trials involving adult smokers, recently or currently receiving inpatient or outpatient treatment for substance use disorders were reviewed. Databases, grey literature, reference lists and journals were searched for relevant studies between 1990 and August 2014. Two authors extracted data and assessed quality. The primary outcome was biochemically verified continuous abstinence from smoking at 6 or 12 months, secondary outcomes were biochemically verified seven-day point prevalence smoking abstinence (ppa) at 6 or 12 months and substance use outcomes. Heterogeneity between studies precluded pooled analyses of the data.

Results: Seventeen of 847 publications were included. Five studies reported significant effects on smoking cessation: 1) Nicotine patches improved continuous abstinence at six months. 2) Nicotine gum improved continuous abstinence at 12 months. 3) Counselling, contingency management and relapse prevention improved continuous abstinence at six and 12 months. 4) Cognitive behavioural therapy, plus nicotine replacement therapy, improved ppa at six months. 5) A combination of bupropion, nicotine replacement therapy, counselling and contingency management improved ppa at six months. Two studies showed some evidence of improved substance use outcomes with the remaining eight studies measuring substance use outcomes showing no difference.

Conclusions: Nicotine replacement therapy, behavioural support and combination approaches appear to increase smoking abstinence in those treated for substance use disorders. Higher quality studies are required to strengthen the evidence base.

**Keywords: Smoking cessation, Substance misuse, Alcohol, Drugs, Tobacco, Intervention**

**INTRODUCTION**

Tobacco use is one of the main risk factors for many chronic illnesses including cancer, lung diseases and cardiovascular diseases, making it one of the largest preventable causes of premature death and disease across the world. Tobacco kills nearly six million people each year and this could rise to eight million by 2030 1.

Smoking is particularly prevalent in the population of those in treatment or recovery from substance use disorders. Between 74% and 98% of patients with substance use disorders are also smokers 2–6. Many patients with substance use disorders may overcome their primary addiction and then die from a tobacco related illness 7. For example, in a cohort of former alcoholics and patients with drug dependence, 51% of deaths were from tobacco related causes 8.

Smoking may be seen as beneficial when giving up alcohol or drugs 9, for example through perceptions that it is calming or lessens anxiety, but such perceptions are likely due to misattribution given smoking relieves nicotine withdrawal 10. In general, smoking has been shown to be an ineffective coping strategy and may worsen substance use treatment outcomes 11,12.

The negative health effects of smoking and the benefits of offering smoking cessation to patients with substance use disorders are well known but more research is needed to identify successful interventions 5,13. Medication such as nicotine replacement therapy (NRT), varenicline, bupropion, cytisine and behavioural support increases success of quit attempts in the general population of smokers, particularly when combined 14–18 and have been recommended as effective interventions within clinical guidelines for the general population 19. Clinical guidelines for substance use services 20 state that “*Secondary care providers have a duty of care to protect the health of, and promote healthy behaviour among, people who use, their services. This duty of care includes providing effective support to stop smoking or abstain from smoking while using secondary care services” (pp.5-6)*. Smokers should be identified at the first opportunity and provided with advice and support 19. This includes providing pharmacotherapy to support abstinence along with an offer of arranging intensive behavioural support. Common assumptions include that the level of motivation to quit within patients with substance use disorders is low; however, it has been found that patients receiving treatment for substance use disorders are as motivated to quit as smokers in the general population 6,21,22. A further concern is that tobacco cessation will compromise substance use treatment, however a previous review indicates that smoking cessation improves abstinence from alcohol and illicit drugs 11.

This review aimed to evaluate two main questions: 1)What is the effectiveness of different smoking cessation interventions for patients with substance use disorders; 2) What is the impact of smoking cessation treatment on substance use outcomes This extends and updates the findings of a previous meta-analysis11. The quality of included studies was also evaluated. As many substance use disorder services do not offer smoking cessation treatment 23, it is hoped that the findings will provide a clearer direction of how to incorporate smoking cessation into substance use treatment.

**METHODS**

**Search strategy**

Searches were conducted by ST in February 2014 and updated in August 2014. Included literature was published from 1990 onwards. Databases searched were Cinahl, Medline, Psycharticles, Psychbooks, Centre for Reviews and Dissertations, British Library, Web of Science, Science Direct, The Cochrane Library and Swetswise. The search strategy included searching for grey literature using Open Grey, Grey Net, The Medical Research Council, Ethos (British Library), The Universal Index of Doctoral Dissertations and The Conference Proceedings Citation Index. Words relating to smoking cessation and substance use disorders, using combinations of ‘or’ and ‘and’ or free text were adapted as required for each database. The thesaurus and MeSH terms were used to identify associated search terms. The final list of search terms is provided as a supplement (S1).

To identify any additional studies of relevance to the research questions, a search was conducted in the Journal of Substance Abuse Treatment, Drug and Alcohol Dependence, Addictive Behaviours and Addiction for editions between January 2010 and January 2014 as these journals had published the majority of the papers identified for review. Manual searches of reference lists and citation searches were also completed.

**Inclusion and exclusion criteria**

To review the most methodologically sound studies, only randomised controlled trials of smoking cessation interventions with at least six months follow-up, involving smokers over the age of 18, who had recently completed or were currently receiving inpatient or outpatient treatment for a substance use disorder (drugs or alcohol) were included. Interventions could include pharmacological and non-pharmacological approaches in any setting and mode of delivery. Trials had to include two different treatments, one of which could be placebo or usual care. Trials comparing different timings such as concurrent versus delayed implementation of the same intervention were therefore excluded. The question of timing is the subject of a proposed Cochrane review 24. In addition, studies had to report biochemically-verified smoking abstinence outcomes in accordance with the Russell Standard 25.

**Outcome measures**

The primary outcome measure was biochemically verified (carbon monoxide) self-reported continuous abstinence from smoking, at the six or 12 month follow-up 26,27. Secondary outcome measures were biochemically verified self-reported seven-day point prevalence abstinence from smoking (ppa) at six or 12 months follow-up 25,28. Substance use treatment outcomes at six or 12 months were also included. Different studies reported different substance use treatment outcomes. Three studies defined substance use abstinence as self-reported, no substance use over the last week confirmed by urine drug screen or breath alcohol test results 29–31. Two studies defined 30-day point prevalence substance use abstinence as self-reported, no substance use during the 30 days prior to follow-up combined with a breath alcohol test 32 or a breath alcohol and a urine drug screen 33. One study defined continuous substance use abstinence as self-reported, no substance use over the 90 days prior to the follow up time point confirmed by urine drug screen or breath alcohol test results 34. One study defined the proportion of days heavy drinking as the amount of heavy drinking days, 14 days prior follow-up and the 30 days prior to the 3 and 6-month follow-up. A heavy drinking day was defined as any day on which a man drank six or more standard drinks, or a woman drank four or more standard drinks 35. Because little evidence on the effectiveness of interventions in this population is available, for studies reporting no effect at 6 or 12 months, earlier follow-up comparisons were included as secondary outcomes.

**Data analysis**

ST screened the initial titles. ST and LB screened the abstracts and full papers for relevance to the research question. Reasons for exclusion were documented and any discrepancies discussed amongst the reviewers to arrive at a consensus (excluded references in table S2).

Data extraction was carried out by ST and LB using a data extraction sheet designed for randomised controlled trials 36. The data extraction process recorded the following: study aims, population, eligibility criteria, randomisation methods, sample characteristics, intervention type, study setting, recruitment method, study staff, substance type, smoking and substance use outcomes measures, follow-up period and study findings. There was a 95% agreement rate between reviewers and disagreements were resolved through discussion and rechecking the papers. Quality assessment was carried out by ST and LB using the Cochrane tool for assessing bias 36. Where statistical information was available from the paper or by contacting the author, findings were computed into a common effect size statistic of *r* 37.

Due to heterogeneity in terms of the population, control group, length of follow-up and outcome measures, there were no sets of studies that were sufficiently similar to make them suitable for inclusion in a meta-analysis, so a narrative synthesis was used.

**RESULTS**

The screening process led to the identification of 17 studies for inclusion in the review. Figure 1 contains a flow diagram 38 of the screening process. Study characteristics are summarised in Table 1. Study sample size ranged from 64 to 383 participants. Mean age of the participants ranged from 34 years to 50 years. One study contained 100% males, otherwise the percentage of males ranged from 50% to 97%. Mean baseline number of cigarettes smoked per day ranged from 16 to 32.

Eight studies investigated smoking cessation in alcohol treatment only, five investigated alcohol and drug treatment and four investigated drug treatment only. Studies included one or more of the following addictive substances: alcohol, cocaine, heroin, cannabis, amphetamines, methamphetamines and benzodiazepines.

**Treatment status**

Five studies investigated smokers currently in treatment for a substance use disorder. Four studies stated that patients were currently in treatment but enrolled in the intervention after a specific period of abstinence (e.g. seven days abstinence 39, after 30 days abstinence 31,33 or had a substance use diagnosis in the past three months 40). Three studies investigated methadone maintained patients. Five of the studies investigated smokers with a past history or drug or alcohol abuse. This tended to relate to a specific period of abstinence (e.g. at least two months abstinence 41, between two and 12 months abstinence 42 or at least one year of abstinence 43). One study stated that participants had an average of four years abstinence 44 and another study participants had a median of five years of abstinence 45.

**Interventions**

*Setting*

Twelve studies were conducted in outpatient and five in inpatient settings. Intervention settings included long-term and short-term residential treatment, outpatient community treatment centres and outpatient methadone clinics.

*Recruitment method*

Six studies reported recruitment methods, including advertisements in local newspapers or on clinic bulletin boards and asking people to contact the research team to take part. Other methods included recruiting patients through nominations from treatment staff. Three studies used Alcoholics Anonymous (AA) meetings as a way to recruit patients, including one study which appointed members of the AA group as study recruiters. One study gave presentations at treatment clinics until enough patients had enrolled. Overall, 12 studies either required participants to have an intention to quit smoking or recruited participants via posters or other advertising, suggesting that participants were likely to have had some intention or motivation to quit.

*Smoking outcome measures*

One study reported only continuous abstinence at six months, another at six and 12 months follow-up. Four studies reported continuous abstinence and ppa: two at six months, one at six and 12 months and one at 12 months. Eleven studies only measured ppa, as the primary smoking outcome; of these, seven studies reported smoking outcomes at six months only, three studies reported smoking outcomes at six and 12 months and one reported smoking outcomes at 12 months.

*Intervention characteristics*

The intervention characteristics can be seen in Table S3. The studies used a variety of different staff members to deliver the interventions, including research staff, therapists, nurses, physicians and psychiatrists. The main intervention categories included counselling only; counselling and NRT; NRT only; cognitive behavioural treatment (CBT) only; CBT and NRT; motivational interviewing (MI); bupropion and varenicline. One approach, used in three of the interventions 33,46,47 was contingency management (CM) which involves positive reinforcement (use of financial or material incentive) to promote desired behaviours 48.

**Effectiveness of smoking** **cessation interventions**

Five of the 17 studies reported significant effects at six or 12 month follow up. One study 45 found significant differences in continuous abstinence at six months, another study 34 found significant differences in continuous abstinence at 12 but not at six months and a further study found significant differences in continuous abstinence at both six and 12 months 33. Two studies reporting ppa as primary outcome 32,47 found significant differences between interventions, both at six months. Four of the studies provided smoking cessation treatment concurrently with substance use treatment and one provided treatment for patients with a past history of a substance use disorder. Results are detailed in Table S3.

Two studies found evidence that nicotine replacement therapy is of benefit 34,45. For outpatient smokers with a past history of alcohol dependence, 21mg nicotine patches significantly increased continuous abstinence at 4 months and at six months compared with a placebo patch 45. A combination of CBT, nicotine patch and nicotine gum had significantly higher continuous abstinence rates at 12 months than the CBT, nicotine patch and placebo gum condition 34 for outpatient smokers in early treatment for alcohol dependence.

One study found evidence that a behavioural support is of benefit 33. A multicomponent smoking treatment (MST) consisting of five weeks of pre-quit treatment, four weeks of post-quit counselling, individual daily counselling sessions, contingency contracting and relapse prevention training was compared against the same multicomponent smoking treatment plus generalisation training (MST+G) and a usual care condition (UC) 33 for inpatient, newly recovering drug and alcohol dependent smokers. All participants received nicotine patches. The relapse prevention training identified high risk situations and practiced coping skills that could be used in these situations. The generalisation training similarly identified high risk situations common to smoking, drug and alcohol use and involved practicing coping skills to prevent relapse to all substances. Continuous abstinence differed significantly between groups both at six and 12 months, with both intervention groups achieving higher rates than the usual care group. There were no significant differences in ppa at the six month or at 12 month follow-up; although the two intervention groups combined and separately had higher than the usual care group at one-month post quit.

Two studies found evidence that a combination of behavioural support and medication was beneficial to smoking cessation 32,47. Carmody (2012)32provided an intensive intervention consisting of 16 sessions of individualised CBT, 16 weeks of nicotine patches and 26 weeks of nicotine lozenges in comparison with usual care which included a referral to a smoking cessation clinic. PPA was significantly higher for the intensive intervention group at 12 weeks for outpatient alcohol dependent smokers in early recovery and at six months but there was no significant difference at 12 months. Winhusen (2013) 47 randomised outpatient, current stimulant dependent smokers into substance use treatment as usual or substance use treatment as usual plus smoking cessation treatment. Smoking cessation treatment included weekly individualised counselling and bupropion. Further into the intervention, participants were also offered a nicotine inhaler and contingency management. PPA was significantly higher in the intervention group compared to the treatment as usual group at 10 weeks, 3 months and at six month follow-up.

Of the 12 studies that did not find treatment effective at six or 12 months, four observed significant effects at shorter term follow-ups. During one study 46all participants received 12 weeks of nicotine patches and were assigned to one of four conditions: patch only, relapse prevention plus patch, CM plus patch and relapse prevention, or CM plus patch. At 12 weeks, participants assigned to receive CM showed statistically higher rates of ppa than those not assigned to receive contingencies.

Another intervention 31 randomised outpatient smokers from a drug and alcohol dependence treatment program to counselling plus NRT or substance use treatment as usual. The ppa rates were significantly higher in the smoking cessation condition rather than treatment as usual, during week 2- 7 but not at six month follow-up.

When comparing a brief 15 minute counselling session with three intensive 60 minute individual sessions and eight weeks of nicotine patches, ppa was significantly higher for the intensive condition (27.5%) than the brief condition (6.6%) at one month post quit date but not at six month follow-up for outpatient alcohol dependent smokers 40.

Finally, Patten and colleagues 44 compared counselling plus nicotine gum, counselling plus physical exercise and a standard treatment condition for outpatient heavy smokers recovering from alcohol dependence. Short term differences in ppa rates between interventions were significant at post treatment, with higher quit rates in the counselling plus physical exercise condition (60%) compared with standard condition (31%).

For the eight studies where no evidence of effectiveness was found, interventions involved counselling 29, NRT 41,CBT 30, MI 49, bupropion 42,43, varenicline50 and a combination of treatments 51. In relation to inpatient versus outpatient settings, one of the five inpatient studies found significant effects compared with eight of the 12 outpatient studies.

**Effects on substance use outcomes**

Ten of the 17 studies reported the impact of smoking cessation interventions on substance use outcomes. Two of these studies reported a difference in substance use outcomes across conditions. The drug and alcohol abstinence rates were higher in the MST condition rather than the MST+G condition at six and at 12 months follow up 33, although neither differed significantly from that of the usual care condition (figures not reported in paper). There was also a significant difference in drug and alcohol relapse rates between MST and MST+G conditions suggesting that participants in the MST condition had lower relapse rates than those in the MST+G condition. In the Shoptaw study described above 46**,** during weeks where patients with substance use disorders met the criteria for smoking abstinence they also provided more opiate and cocaine-free urine samples. The remaining eight studies did not find any significant difference between conditions in relation to substance use outcomes.

**Quality review**

Overall, many of the details required to determine quality were not reported (Table

2). Only eight studies reported sufficient information on randomisation and three provided adequate information on allocation concealment. Nine studies reported adequate information on blinding of participants or investigators and seven reported adequate information on blinding of outcome assessors. Thirteen studies used intention to treat analysis 52 where all randomised patients were included in their originally assigned groups and missing data was recorded as non-abstinence.

Two studies had a high risk of reporting fewer outcomes than expected or not reporting the use of a protocol. Only five studies reported carrying out power analysis in sufficient detail within the paper with all stating that they sought a power of at least .80. Effect sizes 37 could only be calculated for twelve of the studies where the required information was reported. Of the studies with a significant effect, two studies 32,47 had effect sizes between r=.17 and r =.19 and another had r=.27 34. Two studies had effect sizes 33,45 between r=.32 and r=.47. Three studies without a significant effect at long term follow-up 31,44,51 had effect sizes r<.1, three had effect sizes between r=.10 and r=.19 29,40,50.

**DISCUSSION**

Seventeen randomised controlled trials investigating the effectiveness of smoking cessation interventions, for patients with substance use disorders were identified for inclusion in this review. Five studies reported significant effects on smoking cessation, providing evidence of effectiveness of NRT, behavioural support and combinations of the two, although not all trials testing combination treatments found an effect. Four other studies reported significant intervention effects at shorter follow-ups but not at the required 6 or 12 months, providing weaker evidence to support the effectiveness of NRT, combinations of NRT and behavioural support, as well as some suggestion that contingency management and physical activity may be beneficial. Two studies showed some evidence of improved substance use outcomes. They had in common that the smoking cessation interventions provided a combination of contingency management and relapse prevention. None of the trials suggested a negative effect of smoking cessation treatment on substance use outcomes.

Weaknesses in methods and reporting in some cases, combined with the small number of studies make the conclusion about the effectiveness of these interventions tentative. Many papers did not clearly state how the trials protected against bias, as indicated by the high proportion categorised as ‘unclear risk’ 53,54. Only five studies reported carrying out a power analysis prospectively to determine sample size and it is particularly important to allow for attrition when treating patients with substance use disorders. When calculated, studies reporting significant differences had between small and medium effect sizes 37. Five of the non-significant results had very small effect sizes (<0.1) and would have required a much larger sample size (>700 participants) to achieve adequate power. Alternatively, a more intensive design or longer treatment may have produced stronger effects. None of the studies provided an economic evaluation of the interventions, which is an important factor in determining optimal treatment.

Meta-analysis could not be conducted due to the heterogeneity in the studies including the design, follow-up period and treatment lengths. Due to this we were not able to combine the effect sizes and probabilities found in the studies or combine results of studies to increase the power of statistical tests 55.

Strengths of this review include that it concentrated on randomised controlled trials. This was due to the volume of study designs in this area and the aim of reviewing the most methodologically sound studies. Also, an established quality rating scale 36 was used for data extraction and was completed independently by two authors to minimise any rating errors. The risk of publication bias was minimised through the use of several search mechanisms which strengthen the search strategy. The broad search strategy gives confidence that all currently available evidence has been identified in this review.

These findings update and extend previous review findings as thirteen of the studies were conducted between 2003 and 2014 since the last meta-analysis was carried out 11. This review provides further descriptions of interventions and control conditions as well as recruitment methods, study staff, setting and treatment length to characteristics of a variety of treatment approaches.

NRT and behavioural support and combinations were effective in this population, which is in line with findings in the general population 17,18,56,57 and the recommendations of the previous review for patients with substance use disorders 11. Varenicline was not found to be effective in one trial, which is different from the general population, where it has been found to be one of the most effective medications 58. We also found no evidence for the effectiveness of bupropion, which is effective in the general population 59, although again, there was only two trials investigating this in a substance use population.

Future research should include additional studies of the effectiveness of varenicline and bupropion for substance use disorder populations and address the methodological limitations of the studies included in this review. The aim should be to identify interventions that promote longer term abstinence into the six or 12 month follow-up period, using a measure of continuous abstinence wherever possible. Sample sizes should be planned prospectively to ensure adequate power to identify beneficial interventions. Future research should aim to identify which specific aspects of the combination treatments have a significant effect on smoking outcomes and what effect the mode of delivery or frequency of treatment have on abstinence in this population.

The timing of smoking cessation interventions is an important area of research as the question still remains whether smoking cessation treatment should be offered during substance use disorder treatment or delayed until treatment is complete 24. We did not test this hypothesis in our study but four of the effective studies offered concurrent smoking cessation and substance use disorder treatment suggesting that concurrent treatment of smoking alongside other treatment can be successful.

Barriers to implementing smoking cessation interventions for patients with substance use disorders include limited knowledge of how to engage this population into treatment and a belief that stopping smoking may affect recovery from other substances 60. Incorporating smoking cessation into substance use disorder treatment gives a clear message that quitting smoking is a major health priority. Patients with substance use disorders may require more intensive interventions to treat a number of addictions and tobacco is often viewed as a less harmful alternative to drugs and alcohol 12. Besides its addictive properties, cigarette smoking is legal and socially acceptable in many settings, giving it greater availability than other drugs 61. Treatment providers may need to employ strategies to avoid attrition, maintain motivation and make it as easy as possible to access the clinic. Modern smoking cessation approaches could be investigated; for example, e-cigarettes and mobile apps have yet to be tested as interventions in this population although risks and benefits associated with e-cigarette use are still under investigation.

**Conclusions**

Smoking cessation interventions using nicotine replacement therapy, behavioural support and combination approaches appear to increase smoking abstinence in those treated for substance use disorders and have no effect on other substance use treatment outcomes. However, higher quality studies and reporting are required to strengthen the evidence base.

**Funding**

This work was supported by the UK Centre for Tobacco and Alcohol Studies (RES-590-28-0004) [LB&AM], a UKCRC Public Health Research Centre of Excellence. Funding from the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged [LB & AM]. No other funding was used for this research.

**Conflict of Interest** No conflict declared**.**

**Acknowledgements**

Thanks to Dr Rachel Povey and Dr Owen Richardson for reviewing and commenting on earlier drafts of this paper and to Vera Stanley for proof-reading.

**References**

1. World Health Organisation. Tobacco. *Fact Sheet 339*. 2014.

2. Best D, Lehmann P, Gossop M, Harris J, Noble A, Strang J. Eating Too Little, Smoking and Drinking Too Much: Wider Lifestyle Problems Among Methadone Maintenance Patients. *Addict Res Theory*. 1998;6:489-498. doi:10.3109/16066359809004367.

3. Kalman D. Smoking cessation treatment for substance misusers in early recovery: a review of the literature and recommendations for practice. *Subst Use Misuse*. 1998;33:2021-2047. doi:10.3109/10826089809069815.

4. Tacke U, Wolff K, Finch E, Strang J. The effect of tobacco smoking on subjective symptoms of inadequacy of methadone dose among opiate addicts in methadone maintenance treatment. *Addict Biol*. 2001;6:137-145. doi:10.1080/13556210020040217.

5. McCarthy WJ, Collins C, Hser Y-I. Does Cigarette Smoking Affect Drug Abuse Treatment? *J Drug Issues*. 2002;32:61-79. doi:10.1177/002204260203200103.

6. Cookson C, Strang J, Ratschen E, Sutherland G, Finch E, McNeill A. Smoking and its treatment in addiction services: Clients’ and staff behaviour and attitudes. *BMC Health Serv Res*. 2014;14(1):304. doi:10.1186/1472-6963-14-304.

7. Richter KP. Good and bad times for treating cigarette smoking in drug treatment. *J Psychoactive Drugs*. 2006;38:311-315. doi:10.1080/02791072.2006.10399857.

8. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. *JAMA*. 1996;275:1097-1103. doi:10.1001/jama.275.14.1097.

9. West R. *The SmokeFree Formula: A Revolutionary Way to Stop Smoking Now*. London: Orion; 2013.

10. Taylor G, McNeill A, Girling A. Change in mental health after smoking cessation: systematic review and meta-analysis. *Br Med J*. 2014;1151:1-22.

11. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. *J Consult Clin Psychol*. 2004;72:1144-1156. doi:10.1037/0022-006X.72.6.1144.

12. Prochaska JJ. Failure to treat tobacco use in mental health and addiction treatment settings: A form of harm reduction? *Drug Alcohol Depend*. 2010;110:177-182. doi:10.1016/j.drugalcdep.2010.03.002.

13. Tsoh JY, Chi FW, Mertens JR, Weisner CM. Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes. *Drug Alcohol Depend*. 2011;114:110-118. doi:10.1016/j.drugalcdep.2010.09.008.

14. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation (Review). *Cochrane Collab*. 2012. doi:10.1002/14651858.CD006103.pub6.

15. Leaviss J, Sullivan W, Ren S, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. *Health Technol Assess (Rockv)*. 2014;18:1-120. doi:10.3310/hta18330.

16. Piné-Abata H, McNeill A, Murray R, Bitton A, Rigotti N, Raw M. A survey of tobacco dependence treatment services in 121 countries. *Addiction*. 2013;108(8):1476-1484. doi:10.1111/add.12172.

17. Stead L, Lancaster T. Group behaviour therapy programmes for smoking cessation ( Review ). *Cochrane Collab*. 2005;CD001007(2). doi:10.1002/14651858.CD001007.

18. Lancaster T, Stead L. Individual behavioural counselling for smoking cessation. *Cochrane Database Syst Rev*. 2005;CD001292. doi:10.1002/14651858.CD001292.pub2.

19. National Institute for Health and Care Excellence. *Smoking Cessation Services*.; 2008. doi:10.1038/bdj.2007.1230.

20. National Institute for Health and Care Excellence. *Smoking Cessation in Secondary Care : Acute , Maternity and Mental Health Services*.; 2013. guidance.nice.org.uk/ph48.

21. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *J Stud Alcohol*. 2004;65:681-691. doi:10.15288/jsa.2004.65.681.

22. Hall SM, Prochaska JJ. Treatment of Smokers with Co-Occuring Disorders: Emphasis on Intergration in Mental Health and Addiction Treatment Settings. *Annu Rev Clin Psychol*. 2009;5:409-431. doi:10.1146/annurev.clinpsy.032408.153614.

23. Knudsen HK, Studts JL, Boyd S, Roman PM. Structural and cultural barriers to the adoption of smoking cessation services in addiction treatment organizations. *J Addict Dis*. 2010;29:294-305. doi:10.1080/10550887.2010.489446.

24. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. *Cochrane Libr*. 2012;12:1-10. doi:10.1002/14651858.CD010274.

25. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100:299-303. doi:10.1111/j.1360-0443.2004.00995.x.

26. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. *Efficacy of Nicotine Patch in Smokers with a History of Alcoholism.*; 2003. doi:10.1097/01.ALC.0000071742.86555.4D.

27. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100:299-303. doi:10.1111/j.1360-0443.2004.00995.x.

28. Velicer W, Prochaska J, Rossi J, Snow M. Assessing Outcome in Smoking Cessation Studies. *Psychol Bull*. 1992;111:23-41. doi:10.1037/0033-2909.111.1.23.

29. Gariti P, Alterman A, Mulvaney F, et al. Nicotine intervention during detoxification and treatment for other substance use. *Am J Drug Alcohol Abuse*. 2002;28:671-679. doi:10.1081/ADA-120015875.

30. Mueller S, Petitjean S, Wiesbeck G. Cognitive behavioral smoking cessation during alcohol detoxification treatment: a randomized, controlled trial. *Drug Alcohol Depend*. 2012;126:279-285. doi:10.1016/j.drugalcdep.2012.05.026.

31. Reid M, Fallon B, Sonne S, et al. Smoking cessation treatment in community-based substance abuse rehabilitation programs. *J Subst Abuse Treat*. 2008;35:68-77. doi:10.1016/j.jsat.2007.08.010.

32. Carmody TP, Delucchi K, Duncan CL, et al. Intensive intervention for alcohol-dependent smokers in early recovery: a randomized trial. *Drug Alcohol Depend*. 2012;122:186-194. doi:10.1016/j.drugalcdep.2011.09.026.

33. Burling T a., Seidner Burling A, Latini D. A controlled smoking cessation trial for substance-dependent inpatients. *J Consult Clin Psychol*. 2001;69:295-304. doi:10.1037//0022-006X.69.2.295.

34. Cooney NL, Cooney JL, Perry BL, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction*. 2009;104:1588-1596. doi:10.1111/j.1360-0443.2009.02624.x.

35. Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Concurrent brief versus intensive smoking intervention during alcohol dependence treatment. *Psychol Addict Behav*. 2007;21(4):570-575. doi:10.1037/0893-164X.21.4.570.

36. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Collab*. 2011;5.1.0([updated March 2011]). www.cochrane-handbook.org.

37. Cohen J. A Power Primer. *Psychol Bull*. 1992;112:155-159.

38. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. *Int J Surg*. 2011;9:672-677. doi:10.1016/j.ijsu.2010.09.006.

39. Carmody TP, Delucchi K, Duncan CL, et al. Intensive intervention for alcohol-dependent smokers in early recovery: a randomized trial. *Drug Alcohol Depend*. 2012;122(3):186-194. doi:10.1016/j.drugalcdep.2011.09.026.

40. Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Concurrent brief versus intensive smoking intervention during alcohol dependence treatment. *Psychol Addict Behav*. 2007;21:570-575. doi:10.1037/0893-164X.21.4.570.

41. Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. *J Subst Abuse Treat*. 2006;30:213-217. doi:10.1016/j.jsat.2006.01.001.

42. Kalman D, Herz L, Monti P, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: Results from a randomized, double-blind, placebo-controlled study. *Drug Alcohol Depend*. 2011;118(2-3):111-118. doi:10.1016/j.drugalcdep.2011.03.005.

43. Hays TJ, Hurt RD, Decker P a, Croghan IT, Offord KP, Patten C a. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. *Nicotine Tob Res*. 2009;11(7):859-867. doi:10.1093/ntr/ntp077.

44. Patten C a., Martin JE, Calfas KJ, Lento J, Wolter TD. Behavioral treatment for smokers with a history of alcoholism: Predictors of successful outcome. *J Consult Clin Psychol*. 2001;69:796-801. doi:10.1037/0022-006X.69.5.796.

45. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of Nicotine Patch in Smokers With a History of Alcoholism. *Alcohol Clin Exp Res*. 2003;27:946-954. doi:10.1097/01.ALC.0000071742.86555.4D.

46. Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. *Addiction*. 2002;97:1317-1328. doi:10.1046/j.1360-0443.2002.00221.x.

47. Winhusen TM, Brigham GS, Kropp F, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. *J Clin Psychiatry*. 2013:336-343. doi:10.4088/JCR.13m08449.

48. Weaver T, Metrebian N, Hellier J, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. *Lancet*. 2014;384(9938):153-163. doi:10.1016/S0140-6736(14)60196-3.

49. Rohsenow DJ, Martin R a, Monti PM, et al. Motivational interviewing versus brief advice for cigarette smokers in residential alcohol treatment. *J Subst Abuse Treat*. 2014;46:346-355. doi:10.1016/j.jsat.2013.10.002.

50. Stein M, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. *Drug Alcohol Depend*. 2013;133:486-493. doi:10.1016/j.drugalcdep.2013.07.005.

51. Stein M, Weinstock MC, Herman DS, Anderson BJ, Anthony JL, Niaura R. A smoking cessation intervention for the methadone-maintained. *Addiction*. 2006;101:599-607. doi:10.1111/j.1360-0443.2006.01406.x.

52. Fisher L, Dixon D, Herson J, Frankowski R, Hearron M, Peace K. Intention to treat in clinical trials. In: Peace K, ed. *Statistical Issues in Drug Research and Development*. New York: Marcel Dekker; 1990:331-350.

53. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. *Br Med J*. 2001;323:42-46. doi:10.1136/bmj.323.7303.42.

54. Verhagen A, de Vet H, de Bie R, Boers M, van den Brandt P. The art of quality assessment of RCTs included in systematic reviews. *J Clin Epidemiol*. 2001;54:651-654. doi:10.1016/S0895-4356(00)00360-7.

55. Clark-Carter D. *Quantitative Psychological Research*. 3rd ed. East Sussex: Psychology Press; 2010.

56. Stead L, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev*. 2012;CD008286(10). doi:10.1002/14651858.CD008286.pub2.

57. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation (Review). *Cochrane Database Syst Rev*. 2008;(1):CD000146. doi:10.1002/14651858.CD000146.pub3.

58. Cahill K, Stevens S. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*. 2013;CD009329(5). doi:10.1002/14651858.CD008286.pub2.

59. Hughes J, Stead L, Cahill K, Lancaster T. Antidepressants for smoking cessation ( Review ). *Cochrane Libr*. 2014;CD000031(1):1-145. doi:10.1002/14651858.CD000031.pub3.Copyright.

60. Mackowick KM, Lynch MJ, Weinberger AH, George TP. Treatment of tobacco dependence in people with mental health and addictive disorders. *Curr Psychiatry Rep*. 2012;14:478-485. doi:10.1007/s11920-012-0299-2.

61. Reid M, Selzer J, Rotrosen J. Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs. *Northeast ATTC Resour Links*. 2006;5:2-5.